The short version of DAC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-04 and is reviewed periodically as new material appears.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
== Epidemiology == The incidence of urethral diverticulum has been increasing in the 2000s, likely due to increasing diagnosis and detection of the condition. It is estimated to be present in as low as 0.02% of all women and as high as 6% of all women, and 40% of women with lower urinary tract symptoms. Most symptomatic urethral diverticula are present in women from 30 to 60 years old. 84% of periurethral masses are due to urethral diverticula.
Valve Corporation, also known as Valve Software, is an American video game developer, publisher, hardware, and digital distribution company headquartered in Bellevue, Washington. It is the developer of game franchises including Half-Life, Counter-Strike, Portal, Team Fortress, Left 4 Dead and Dota, the software service Steam, and hardware including the Steam Frame, Steam Machine, Steam Deck and Valve Index. Valve was founded in 1996 by former Microsoft employees Gabe Newell and Mike Harrington. Their debut game, the first-person shooter (FPS) Half-Life (1998), was a critical and commercial success that had a lasting influence on the genre. Harrington left in 2000. In 2003, Valve launched Steam, followed by Half-Life 2 (2004), the episodic sequels Half-Life 2: Episode One (2006) and Episode Two (2007), the puzzle games Portal (2007) and Portal 2 (2011), and the multiplayer games Team Fortress 2 (2007), Left 4 Dead (2008), and Dota 2 (2013). During the 2010s, Valve released fewer games and focused on hardware and virtual reality (VR). They released the first Steam Machine console in 2015, the Valve Index VR headset in 2019, their flagship VR game, Half-Life: Alyx, in 2020, and the handheld system Steam Deck in 2022. In 2026, Valve released a redesigned Steam Machine and a standalone VR headset, the Steam Frame. Valve uses a flat organizational structure, allowing employees to choose their own projects. Valve is noted for its technical and artistic innovation, with many of its games receiving mention among the greatest games of all time.
== History of adipose-derived hormones == It had been shown that adipose tissue secreted some unknown factor that influenced appetite. However, the importance of adipose tissue as an endocrine organ was only fully appreciated in 1995 with the discovery of leptin, the protein product of the Ob gene. Leptin is a strong appetite suppressant that, when depleted, causes early onset severe obesity in humans and in animal models. Low levels of leptin in the blood plasma have been heavily associated with people who have moderate to severe forms of depression. Leptin is known to influence moods and cognition by inducing some structural and functional changes within the hippocampus and prefrontal cortex. Also, leptin has been shown to activate signal transduction pathways associated with dopamine and mTOR, which can increase synaptogenesis. Leptin's role in neuroplasticity is currently still being elucidated, but it has been proven to be active in regions of the brain closely linked to depression. It was found that leptin has antidepressant-like effects similar to that of selective serotonin reuptake inhibitors (SSRIs). The discovery of leptin and its effects on appetite led to hopes of a treatment for obesity and type 2 diabetes, a major disease in the developed world. Unfortunately, clinical studies using leptin as a treatment for obesity in humans failed to show improvement, leading some scientists to conclude that the brain can become resistant to leptin, even at supra-physiological levels (the so-called "ceiling effect"), rendering treatment with leptin ineffective.
Geraniol 8-hydroxylase is a cytochrome P450 protein containing heme. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate (NADPH).
== Cause == The cause of PAH is unknown. Idiopathic PAH (WHO group 1.1) is not associated with an underlying disease or exposure. It is estimated that 39-46% of those with PAH have the idiopathic variant. Group 1.2 PAH includes the variants that are heritable. Genetic variants or mutations in bone morphogenic protein receptor 2 (BMPR2) account for approximately 75-80% of cases of heritable PAH. BMPR2 mutations are also seen in 20% of idiopathic PAH. BMPR2 is a protein involved in endothelial cell (cells that line blood vessels) proliferation and remodeling. Other types of genes coding for proteins involved in BMPR2 signaling have also been implicated as causes of heritable PAH, such as activin A receptor type-2-like-1 ACVRL1, Endoglin (ENG), SMAD genes encoding for SMAD transcription factors involved in downstream BMPR2 signaling and cell growth including Smad1, Smad4 and Smad9. KCNK3 encodes for a potassium channel which regulates membrane potential across cells thus controlling vascular tone. Eukaryotic translation initiation factor 2 alpha kinase 4 (E1F2AK4) is mutated causes heritable pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Group 1.3 PAH includes disease that is due to drug or toxin exposures. Methamphetamines, the chemotherapeutic dasatinib and the appetite suppressant and diet drug fenfluramine are associated with PAH. Group 1.4 PAH is disease that is associated with underlying disease.
Sources: en.wikipedia.org
=== 2024 discontinuation === In September 2024, the forums were discontinued by Bodybuilding.com, and its webpages redirected to a company statement which mentioned: "No good growth came without change. We're building new ways to connect our global community". This was highly controversial among the site's long-time visitors. Many of its users migrated to successor forums, mainly Newmisc.com. As of May 2026, the forums are to be on track to return; when users visit the forums section of the website they're prompted with a splash screen stating such.
== See also == Proposals for a Jewish state Jewish Autonomous Oblast Jewish and democratic state Jewish state Land of Israel/ Palestine History of Israel/ History of the Palestinian people/History of the Jews and Judaism in the Land of Israel Binational solution Jewish Agency for Israel 1947 UN Partition Plan Christian Zionism
Fosfomycin, sold under the brand name Monurol among others, is an antibiotic primarily used to treat lower urinary tract infections. It is not indicated for kidney infections. Occasionally it is used for prostate infections. It is generally taken by mouth. Common side effects include diarrhea, nausea, headache, and vaginal yeast infections. Severe side effects may include anaphylaxis and Clostridioides difficile-associated diarrhea. While use during pregnancy has not been found to be harmful, such use is not recommended. A single dose when breastfeeding appears safe. Fosfomycin works by interfering with the production of the bacterial cell wall. Fosfomycin was discovered in 1969 and approved for medical use in the United States in 1996 It is on the World Health Organization's List of Essential Medicines. The World Health Organization classifies fosfomycin as critically important for human medicine. It is available as a generic medication. It was originally produced by certain types of Streptomyces, although it is now made chemically.
==== India ==== Following the expiration of the semaglutide patent in India in March 2026, several domestic pharmaceutical companies launched generic versions of the drug for the treatment of type 2 diabetes and obesity. These included Sun Pharmaceutical Industries (Sematrinity and Noveltreat), Dr. Reddy's Laboratories (Obeda), Zydus Lifesciences (Alterme, Mashema and Semaglyn), Torrent Pharmaceuticals (Sembolic and Semalix), Alkem Laboratories (Semasize, Obesema and Hepaglide), Glenmark Pharmaceuticals (Glipiq) and Eris Lifesciences (Sundae). Others, including Natco Pharma (Semanat and Semafull) and Mankind Pharma also planned product launches around the same time, and in total, 40–50 total brands of semaglutide were expected to become available in India in the following months.
==== Experiments ==== A small amount of one enantiomer at the start of a reaction can lead to a large enantioenrichment in the product. For example, the Soai reaction is autocatalytic. If the reaction is started with some of one of the product enantiomers already present, the product can catalyze the production of more of that same enantiomer.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.